AAAAAA

   
Results: 1-13 |
Results: 13
Dopamine D-3 agonists
Authors: Emilien, G Durlach, C Aveaux, D Maloteaux, JM
Citation: G. Emilien et al., Dopamine D-3 agonists, EXPERT OP T, 11(11), 2001, pp. 1713-1728
Life after sequencing
Authors: Emilien, G Misteli, C Aveaux, D Maloteaux, JM
Citation: G. Emilien et al., Life after sequencing, TRENDS BIOT, 19(7), 2001, pp. 246-246
Impact of genomics on drug discovery and clinical medicine
Authors: Emilien, G Ponchon, M Caldas, C Isacson, O Maloteaux, JM
Citation: G. Emilien et al., Impact of genomics on drug discovery and clinical medicine, QJM-MON J A, 93(7), 2000, pp. 391-423
Post-traumatic stress disorder: Hypotheses from clinical neuropsychology and psychopharmacology research
Authors: Emilien, G Penasse, C Charles, G Martin, D Lasseaux, L Waltregny, A
Citation: G. Emilien et al., Post-traumatic stress disorder: Hypotheses from clinical neuropsychology and psychopharmacology research, INT J PSYC, 4(1), 2000, pp. 3-18
Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia
Authors: Hedner, J Yaeche, R Emilien, G Farr, I Salinas, E
Citation: J. Hedner et al., Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia, INT J GER P, 15(8), 2000, pp. 704-712
The dose-response relationship in Phase I clinical trials and beyond: use,meaning, and assessment
Authors: Emilien, G van Meurs, W Maloteaux, JM
Citation: G. Emilien et al., The dose-response relationship in Phase I clinical trials and beyond: use,meaning, and assessment, PHARM THERA, 88(1), 2000, pp. 33-58
Haemophilias: advances towards genetic engineering replacement therapy
Authors: Emilien, G Maloteaux, JM Penasse, C Goodeve, A Casimir, C
Citation: G. Emilien et al., Haemophilias: advances towards genetic engineering replacement therapy, CLIN LAB H, 22(6), 2000, pp. 313-323
Prospects for pharmacological intervention in Alzheimer disease
Authors: Emilien, G Beyreuther, K Masters, CL Maloteaux, JM
Citation: G. Emilien et al., Prospects for pharmacological intervention in Alzheimer disease, ARCH NEUROL, 57(4), 2000, pp. 454-459
Alzheimer disease - Mouse models pave the way for therapeutic opportunities
Authors: Emilien, G Maloteaux, JM Beyreuther, K Masters, CL
Citation: G. Emilien et al., Alzheimer disease - Mouse models pave the way for therapeutic opportunities, ARCH NEUROL, 57(2), 2000, pp. 176-181
Circadian system and sleep anomaly in depression
Authors: Emilien, G Maloteaux, JM
Citation: G. Emilien et Jm. Maloteaux, Circadian system and sleep anomaly in depression, IRIS J PS M, 16(1), 1999, pp. 18-23
Dopamine receptors - physiological understanding to therapeutic intervention potential
Authors: Emilien, G Maloteaux, JM Geurts, M Hoogenberg, K Cragg, S
Citation: G. Emilien et al., Dopamine receptors - physiological understanding to therapeutic intervention potential, PHARM THERA, 84(2), 1999, pp. 133-156
Pharmacological management of diabetes: Recent progress and future perspective in daily drug treatment
Authors: Emilien, G Maloteaux, JM Ponchon, M
Citation: G. Emilien et al., Pharmacological management of diabetes: Recent progress and future perspective in daily drug treatment, PHARM THERA, 81(1), 1999, pp. 37-51
Sleep latency is shortened during 4 weeks of treatment with zaleplon a novel nonbenzodiazepine hypnotic
Authors: Elie, R Ruther, E Farr, I Emilien, G Salinas, E
Citation: R. Elie et al., Sleep latency is shortened during 4 weeks of treatment with zaleplon a novel nonbenzodiazepine hypnotic, J CLIN PSY, 60(8), 1999, pp. 536-544
Risultati: 1-13 |